GURU.Markets stock price, segment price, and overall market index valuation
The company's share price BPMC
Blueprint Medicines is a biopharmaceutical company specializing in targeted cancer therapy. Its stock price reflects the success of its approved drugs in commercializing them and the potential of its extensive pipeline of precision oncology developments.
Share prices of companies in the market segment - Oncology targeted therapy
Blueprint Medicines is a biopharmaceutical company developing highly selective targeted therapies for the treatment of cancer and rare hematological diseases. We have classified the company in the "Targeted Oncology" segment. The chart below shows how the market views precision medicine approaches.
Broad Market Index - GURU.Markets
Blueprint Medicines is a biopharmaceutical company specializing in the development of targeted therapies for the treatment of cancer and rare genetic diseases. Its focus on precision medicine makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Blueprint compares to it.
Change in the price of a company, segment, and market as a whole per day
BPMC - Daily change in the company's share price BPMC
Blueprint Medicines Corp.'s daily stock price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the stock's sensitivity to sales of its oncology drugs and new research data.
Daily change in the price of a set of shares in a market segment - Oncology targeted therapy
Blueprint Medicines is a biopharmaceutical company specializing in the development of precision-targeted therapies for the treatment of cancer and rare diseases. Oncology is a volatile sector. The chart below reflects average fluctuations in this industry, providing context for evaluating BPMC stock.
Daily change in the price of a broad market stock, index - GURU.Markets
Blueprint Medicines is a biotech company specializing in the development of targeted therapies for cancer treatment. Its shares are buoyed by anticipation of clinical trial results. These sharp movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization BPMC
For Blueprint Medicines, year-over-year performance is a story about its targeted drug discovery platform. Its 12-month market cap growth reflects both sales of its approved drugs for rare cancers and progress in its extensive clinical pipeline. Its valuation is a bet that its scientific approach will continue to bear fruit.
Annual dynamics of market capitalization of the market segment - Oncology targeted therapy
Blueprint Medicines Corporation is a leader in precision medicine, developing targeted therapies for cancer and rare diseases. This chart shows how its scientific advancements, strong R&D pipeline, and ability to successfully commercialize its innovative drugs contribute to its leading growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Blueprint Medicines, a biopharmaceutical company specializing in precision medicine for the treatment of cancer and rare diseases, has a proven track record of commercial success. Its year-over-year market capitalization reflects both sales growth for existing drugs and expectations for new developments.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization BPMC
Blueprint is a commercial-stage oncology company. Its monthly performance reflects both sales growth of its approved targeted therapies and progress in its clinical pipeline. Quarterly revenue reports and trial data are the primary drivers.
Monthly dynamics of market capitalization of the market segment - Oncology targeted therapy
Blueprint Medicines is a leader in precision medicine, developing targeted drugs for the treatment of cancers with specific genetic mutations. The chart below shows how investors assessed the prospects of companies at the forefront of personalized oncology and developing treatments for specific patient groups.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Blueprint Medicines is a commercial biotech company specializing in targeted cancer therapy. Its stock price is driven by a combination of sales growth of its approved drugs and anticipation of new developments. It's a story driven by both commercial and scientific considerations.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization BPMC
Blueprint Medicines, a company developing targeted cancer treatments, shares reflect its commercial and scientific success. Weekly price movements depend on sales data for approved drugs and the results of new clinical trials. The chart below shows how short-term events influence the valuation of this innovative oncology company.
Weekly dynamics of market capitalization of the market segment - Oncology targeted therapy
Blueprint Medicines specializes in developing highly targeted therapies for cancer and rare diseases. Its success is based on a deep understanding of genetics. The chart shows how its scientific breakthroughs enable its stock to outperform the broader oncology sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Blueprint Medicines is a biotech company. This chart shows how its weekly performance, like that of other biotechs, is detached from the market. Its stock price movements are driven by clinical trial news and regulatory decisions, not macroeconomic data.
Market capitalization of the company, segment and market as a whole
BPMC - Market capitalization of the company BPMC
Blueprint Medicines Corporation's market capitalization reflects its success in precision medicine. Its market capitalization chart shows how investors view its ability to develop targeted drugs for the treatment of rare cancers caused by specific genetic mutations.
BPMC - Share of the company's market capitalization BPMC within the market segment - Oncology targeted therapy
Blueprint Medicines' market share in oncology reflects its leadership in precision medicine. Its significant market share reflects its ability to develop and commercialize highly effective targeted therapies that target specific genetic drivers of cancer.
Market capitalization of the market segment - Oncology targeted therapy
The chart below is a barometer of the biotech sector focused on precision oncology. Blueprint Medicines is a leader in this field. The dynamics in the chart reflect how the market values companies developing targeted drugs for patients with specific genetic mutations.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes the market value of precision oncology. Blueprint Medicines' market value is determined by its ability to develop targeted cancer drugs with specific genetic drivers. Its share of the economy is determined by the growing presence of "smart" drugs that are transforming treatment approaches.
Book value capitalization of the company, segment and market as a whole
BPMC - Book value capitalization of the company BPMC
The graph below shows Blueprint Medicines' scientific and commercial foundation. Its line represents the value of the intellectual property in its portfolio of approved targeted cancer therapy drugs. Growth on the graph signifies commercial success and continued investment in research and development of new drugs.
BPMC - Share of the company's book capitalization BPMC within the market segment - Oncology targeted therapy
Blueprint Medicines' core assets are its R&D centers and laboratories, where it develops precision-targeted drugs for the treatment of cancer and rare diseases. The chart shows the company's share of this cutting-edge scientific infrastructure, which forms the foundation for its innovations in precision medicine.
Market segment balance sheet capitalization - Oncology targeted therapy
Biotechnology is a world of contrasts. The graph shows the massive factories of pharmaceutical giants. Blueprint Medicines, a developer of targeted therapies, has a more streamlined model. Its value lies in its intellectual property, not in its scale.
Book value of all companies included in the broad market index - GURU.Markets
Blueprint Medicines is a pharmaceutical company specializing in the development of precision-targeted therapies for cancer and rare diseases. Its assets include a powerful research platform and a portfolio of approved drugs. The chart below reveals the financial clout behind this "molecular sniper."
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - BPMC
Blueprint Medicines is a company specializing in the development of precision (targeted) cancer therapies. It already has approved drugs. The chart will show how the market views both current sales and the potential of its scientific platform for developing new drugs.
Market to book capitalization ratio in a market segment - Oncology targeted therapy
Blueprint Medicines Corporation is a biotechnology company specializing in the development of targeted therapies for cancer treatment. Its value lies in its robust pipeline. This chart shows how the market valuation, reflecting the potential of its drugs, is many times greater than its book value.
Market to book capitalization ratio for the market as a whole
Blueprint Medicines is a biopharmaceutical company specializing in the development of precision-targeted therapies for cancer and rare diseases. This chart shows how the market values their scientific platform and pipeline of approved and developing drugs.
Debts of the company, segment and market as a whole
BPMC - Company debts BPMC
Blueprint Medicines, a biotech company specializing in precision medicine, leverages its financial structure to commercialize its approved drugs and fund its extensive R&D portfolio. This chart shows how the company reinvests revenues into research to develop new targeted drugs for cancer and rare diseases.
Market segment debts - Oncology targeted therapy
Blueprint Medicines is a biopharmaceutical company specializing in the development of targeted therapies for cancer and rare diseases with specific genetic drivers. This chart shows how its leverage reflects the successful transition from clinical development to commercialization of several products, which requires investments in marketing and sales.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio BPMC
BP Prudhoe Bay Royalty Trust is a trust that receives royalties from oil production at the Prudhoe Bay field in Alaska. It has no operating activities. This chart likely shows no debt, as the trust's structure is extremely simple: collect revenue and distribute it among unitholders.
Market segment debt to market segment book capitalization - Oncology targeted therapy
Blueprint Medicines is a biopharmaceutical company focused on developing targeted therapies for cancer and hematological diseases. This chart compares its debt to the total market capitalization of the entire oncology sector. It shows how the company funds its research in precision medicine.
Debt to book value of all companies in the market
Blueprint Medicines is a biopharmaceutical company specializing in the development of precision medicines for cancer and rare diseases. Its approach is based on a deep understanding of genetics. This chart of total market debt helps understand the financial environment in which the company raises capital for its cutting-edge and expensive R&D programs.
P/E of the company, segment and market as a whole
P/E - BPMC
This metric for Blueprint Medicines, an oncology company, represents a valuation based on its drugs. The P/E will reflect both sales of already approved drugs and investors' faith in its scientific platform for developing precision cancer treatments, which justifies the high valuation.
P/E of the market segment - Oncology targeted therapy
Blueprint Medicines is a biopharmaceutical company pioneering precision medicine. It develops targeted therapies that target specific genetic drivers of cancer and rare diseases. This chart shows the average valuation for the oncology sector, reflecting how highly investors value the company's scientific approach and ability to develop highly effective drugs.
P/E of the market as a whole
Blueprint Medicines is a biopharmaceutical company specializing in the development of precision medicines for the treatment of cancer and rare diseases. The company has several approved products. This chart, reflecting overall sentiment, helps understand how investors value successful biotech companies with strong portfolios.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company BPMC
Blueprint Medicines is a biopharmaceutical company specializing in the development of targeted therapies for the treatment of cancer and rare diseases with specific genetic drivers. This chart reflects future revenue expectations, which depend on successful sales of its drugs and the expansion of their use.
%20P%2FE%20BPMC&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-BPMC&v=1772440688774 "Chart of the company's future (projected) P/E BPMC")
Future (projected) P/E of the market segment - Oncology targeted therapy
Blueprint Medicines is a biopharmaceutical company specializing in the development of precision therapies for cancer and rare diseases. This chart compares its profitability expectations with other oncology companies. It shows how investors value its scientific platform and pipeline of approved drugs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-targeted-therapy&v=1772440688775 "Future (projected) P/E graph of the market segment - Oncology targeted therapy")
Future (projected) P/E of the market as a whole
Blueprint Medicines is a biopharmaceutical company specializing in the development of targeted therapies for the treatment of cancer and rare genetic diseases. Its success depends on the results of clinical trials and sales of approved drugs. This chart, reflecting market optimism, influences biotech company valuations and the availability of capital for R&D.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772440688776 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit BPMC
Blueprint Medicines is a biopharmaceutical company specializing in the development of precision medicines for the treatment of cancer and rare diseases. Its financial performance is driven by sales growth of its approved products and success in R&D. This chart illustrates the company's transformation into an integrated commercial organization.
Profit of companies in the market segment - Oncology targeted therapy
Blueprint Medicines is a biopharmaceutical company specializing in the development of targeted therapies for the treatment of cancer and rare genetic diseases. This graph, showing overall sector profitability, reflects progress in precision medicine. Blueprint's success in developing highly effective drugs for patients with specific mutations directly impacts the oncology field.
Overall market profit
Blueprint Medicines is a leader in precision medicine. The company develops targeted drugs that act on specific genetic drivers of cancer and rare diseases. Its scientific approach enables the creation of highly effective medications.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company BPMC
Blueprint Medicines is a biopharmaceutical company developing precision medicines for the treatment of cancer and hematological diseases. Future revenue projections depend on sales of its approved drugs and the success of clinical trials.
%20profit%20of%20the%20company%20BPMC&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-BPMC&v=1772440688783 "Graph of future (projected) profit of the company BPMC")
Future (predicted) profit of companies in the market segment - Oncology targeted therapy
Blueprint Medicines is a biopharmaceutical company specializing in the development of targeted therapies for oncology and hematological diseases. This chart shows future revenue expectations for the entire targeted therapy segment. It allows one to assess how the company's scientific approach to precision medicine fits into these overall forecasts.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-targeted-therapy&v=1772440688784 "Graph of future (predicted) profits of companies in a market segment - Oncology targeted therapy")
Future (predicted) profit of the market as a whole
Blueprint Medicines is a biopharmaceutical company specializing in precision medicine for the treatment of cancer and rare diseases. The company already has commercial products. This schedule is important because it impacts the overall valuation of the sector and the solvency of healthcare systems, which determines the commercial success of its expensive drugs.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772440688787 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - BPMC
Blueprint Medicines is a biopharmaceutical company specializing in the development of precision-targeted therapies for cancer and rare diseases. This metric, which correlates its market capitalization with its drug sales revenue, reflects the success of its scientific platform and represents a significant premium for its ability to create innovative drugs.
P/S market segment - Oncology targeted therapy
Blueprint Medicines is a biopharmaceutical company specializing in precision therapies. It develops targeted drugs for the treatment of cancer and hematological diseases caused by specific genetic mutations. This chart reflects the market's willingness to pay a premium for oncology revenue, demonstrating confidence in Blueprint's scientific platform and drug portfolio.
P/S of the market as a whole
Blueprint Medicines is a biopharmaceutical company specializing in precision therapy, developing targeted drugs for the treatment of genetically specific cancers and hematological diseases. This chart helps understand how the market values companies at the forefront of personalized oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company BPMC
Blueprint Medicines is a biopharmaceutical company specializing in precision therapies for the treatment of cancer and hematological diseases. This chart shows how investors value the company based on projected future sales of its drug portfolio. It reflects their belief in its scientific developments and commercial success.
%20P%2FS%20BPMC&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-BPMC&v=1772440688796 "The graph of the company's future (projected) P/S BPMC")
Future (projected) P/S of the market segment - Oncology targeted therapy
Blueprint Medicines is a biopharmaceutical company specializing in the development of highly selective kinase inhibitors for the treatment of genetically determined cancers and rare diseases. The chart shows the average estimated future sales in the targeted oncology sector. It helps understand how highly investors value the company's scientific platform and drug portfolio.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-targeted-therapy&v=1772440688799 "Future (projected) P/S market segment graph - Oncology targeted therapy")
Future (projected) P/S of the market as a whole
Blueprint Medicines (BPMC) is a biopharmaceutical company specializing in the development of targeted therapies for the treatment of cancer and rare diseases. Their success depends on the sales of their drugs and the results of new research. This graph does not reflect their potential in the field of precision medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772440688803 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales BPMC
Blueprint Medicines' revenue is generated in the precision oncology market. The company sells targeted drugs that target specific genetic mutations that cause cancer. This growth reflects the successful commercialization of its approved drugs and their expanded use across a variety of tumor types.
Sales of companies in the market segment - Oncology targeted therapy
Blueprint Medicines is a biopharmaceutical company specializing in precision therapies for cancer and hematological diseases. Its revenue breakdown shows how revenue is split between sales of its own approved drugs and royalties from partnerships, reflecting its success in targeted oncology.
Overall market sales
Blueprint Medicines Corporation is a biopharmaceutical company specializing in the development of targeted therapies for cancer and rare diseases. Its success depends on the approval and sales of its drugs. Demand for cancer drugs is inelastic, but the overall economics shown in this chart impact the solvency of healthcare systems worldwide, which are the primary purchasers.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company BPMC
Blueprint Medicines is a biopharmaceutical company specializing in the development of precision-targeted drugs for the treatment of cancer and rare diseases. This chart shows analyst expectations for its drug sales and R&D development.
%20sales%20of%20the%20company%20BPMC&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-BPMC&v=1772440688808 "Schedule of future (projected) sales of the company BPMC")
Future (projected) sales of companies in the market segment - Oncology targeted therapy
Blueprint Medicines develops highly selective targeted drugs for the treatment of cancer and rare diseases with specific genetic drivers. This chart shows the forecast for the targeted oncotherapy sector. It reflects the precision medicine paradigm, where treatment is selected based on the tumor's genetic profile.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-targeted-therapy&v=1772440688810 "Schedule of future (projected) sales of companies in the market segment - Oncology targeted therapy")
Future (projected) sales of the market as a whole
This chart, illustrating pharmaceutical investments, is important for Blueprint Medicines. The company develops drugs for targeted cancer therapy. Its commercial success and ability to fund new research depend on the stability of the healthcare system and the willingness to pay for innovative drugs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772440688811 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality BPMC
Blueprint Medicines is a commercial biopharmaceutical company specializing in targeted therapies for cancer and rare genetic diseases. This chart shows its financial performance. Profitability depends on sales growth of approved drugs and the success of its extensive clinical development pipeline.
Market segment marginality - Oncology targeted therapy
Blueprint Medicines is a biopharmaceutical company developing precision medicines for the treatment of cancer and hematological diseases with specific genetic drivers. Profitability depends on the success of its targeted therapies. This chart shows the average profitability in the pharmaceutical industry, helping to assess the strength of its scientific platform.
Market marginality as a whole
Blueprint Medicines is a biopharmaceutical company specializing in the development of targeted therapies for the treatment of cancer and rare diseases. Its growth depends on sales of approved drugs and the success of new developments. This growth curve, reflecting the state of the economy, influences healthcare system budgets, which determine the availability and pricing of innovative oncology drugs.
Employees in the company, segment and market as a whole
Number of employees in the company BPMC
Blueprint Medicines Corporation is a biopharmaceutical company developing and commercializing targeted therapies for the treatment of cancer and rare genetic diseases. This chart shows their growing team of scientists and commercial specialists. Their growth reflects their successful transition from an R&D company to a business with several approved drugs on the market.
Share of the company's employees BPMC within the market segment - Oncology targeted therapy
Blueprint Medicines is a leader in precision medicine, developing targeted therapies for cancer and rare diseases with specific genetic drivers. This chart shows the percentage of all scientists in this field that the company employs, reflecting its robust research platform.
Number of employees in the market segment - Oncology targeted therapy
Blueprint Medicines Corporation is a biopharmaceutical company developing precision drugs for the treatment of cancer and hematological diseases with genetic drivers. This chart, showing employment in the targeted oncology sector, is important. The growing number of scientists in this field reflects a revolution in cancer treatment based on a deep understanding of its genetic causes.
Number of employees in the market as a whole
Blueprint Medicines develops precision medicines for cancer and rare diseases. This employment graph reflects the economic foundation that allows for the funding of personalized medicine. Economic growth drives investment in R&D and allows healthcare systems to afford expensive targeted therapies.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company BPMC (BPMC)
Blueprint Medicines (BPMC) is a biopharmaceutical company specializing in targeted therapies for cancer and rare genetic diseases. This is their "intellectual capital." Their value lies in their scientific platform, which enables them to precisely identify targets. This metric reflects the high valuation of their R&D and drug portfolio.
%20of%20the%20company%20BPMC%20(BPMC)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-BPMC-BPMC&v=1772440688824 "Chart of market capitalization per employee (in thousands of dollars) of the company BPMC (BPMC)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
Blueprint Medicines is a biopharmaceutical company specializing in precision medicine for the treatment of cancer and rare diseases. Its success is based on its ability to accurately identify genetic targets. This demonstrates how the market values a science-based approach, where value is created by intellect rather than personnel.
%20by%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-targeted-therapy&v=1772440688826 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology targeted therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Blueprint Medicines is a biopharmaceutical company specializing in the development of targeted therapies for cancer and rare diseases. Its success is based on a deep understanding of disease genetics. The high employee rating reflects the value of its scientific platform, which enables the development of highly effective drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772440688828 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company BPMC (BPMC)
Blueprint Medicines is a biotech company specializing in precision medicine for cancer and rare diseases. They have approved drugs. This chart shows the balance between the profits their team generates from commercial products and the enormous R&D costs of finding new targeted drugs.
%20Chart%20BPMC%20(BPMC)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-BPMC-BPMC&v=1772440688831 "Company Profit Per Employee (in thousands of dollars) Chart BPMC (BPMC)")
Profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
Blueprint Medicines is a biopharmaceutical company specializing in the development of precision-targeted therapies for cancer and rare genetic diseases. This chart reflects its progression from R&D to commercialization. As sales of its approved drugs grow, this metric demonstrates the strength of its scientific platform.
%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-targeted-therapy&v=1772440688832 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Blueprint Medicines (BPMC) is a biopharmaceutical company developing targeted kinase-based therapies for cancer and rare diseases. It is a biotech company with commercial products. This chart shows how a company with approved, niche drugs generates revenue. Employee performance depends on a high drug price.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772440688834 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee BPMC (BPMC)
Blueprint Medicines is a biopharmaceutical company specializing in targeted cancer therapy. They have approved drugs on the market. This chart demonstrates their commercial success. Their high revenue per employee reflects the value of their innovative drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-BPMC-BPMC&v=1772440688835 "Sales chart per company employee BPMC (BPMC)")
Sales per employee in the market segment - Oncology targeted therapy
Blueprint Medicines is a leader in precision medicine. They develop targeted drugs to treat cancers caused by specific genetic mutations. They already have commercial products. This chart demonstrates the productivity of their R&D engine and commercial team. It reflects their ability to sell these niche, expensive drugs.
Sales per employee for the market as a whole
Collective Mining (CNL) is a junior exploration company focused on finding large copper, gold, and silver deposits in Colombia. Companies at this stage have no sales. This chart for a junior explorer doesn't reflect operational efficiency. It would be zero. The entire staff (geologists and engineers) is focused not on sales but on creating future value through drilling and evaluating potential deposits.
Short shares by company, segment and market as a whole
Shares shorted by company BPMC (BPMC)
Blueprint Medicines (BPMC) is a biotech company focused on targeted cancer therapy. This chart tracks bearish bets. Shorts may be related to the intense competition in the oncology field or concerns about the success of its new developments.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-BPMC-BPMC&v=1772440688838 "Short Shares Chart for the Company BPMC (BPMC)")
Shares shorted by market segment - Oncology targeted therapy
Blueprint Medicines (BPMC) is a biopharmaceutical company specializing in precision (targeted) therapies for cancer and rare diseases. The chart below represents a general short position in the oncology biotech sector. It reflects the investor skepticism about the success of highly specialized clinical trials.
Shares shorted by the overall market
Blueprint Medicines is developing precision (targeted) cancer therapy. This is expensive R&D. This chart illustrates the overall market pessimism. Even with approved drugs, investors may panic. They fear that during a crisis, the healthcare system will put downward pressure on the prices of expensive cancer drugs.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator BPMC (BPMC)
Blueprint Medicines (BPMC) specializes in precision medicine—developing targeted drugs for cancer and rare diseases with known genetic drivers. This oscillator measures momentum. It shows when the stock is "overheated" (above 70) on positive trial data or "oversold" (below 30) on news about competitors or delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-BPMC-BPMC&v=1772440688840 "RSI 14 indicator chart for the company's stock BPMC (BPMC)")
RSI 14 Market Segment - Oncology targeted therapy
Blueprint Medicines is a biotech company specializing in precision medicine. They develop targeted drugs that attack specific genetic drivers of cancer. This chart measures the collective excitement in the oncology biotech sector. It helps determine whether the entire segment is overheated.
RSI 14 for the overall market
For Blueprint Medicines, a biotech company in R&D, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BPMC (BPMC)
Blueprint Medicines is a leader in precision oncology. They develop targeted drugs for the treatment of cancers caused by specific genetic mutations. This chart shows the analysts' average 12-month forecast. It reflects their assessment of the commercial success of their current drugs and the potential of their R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BPMC-BPMC&v=1772440688844 "A chart showing analyst consensus forecasts for the expected stock price. BPMC (BPMC)")
The difference between the consensus estimate and the actual stock price BPMC (BPMC)
Blueprint Medicines (BPMC) is a sharpshooter in oncology. The company is a leader in precision medicine, developing targeted drugs (Ayvakit) for cancers with rare mutations. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and the forecast, reflecting their assessment of the company's R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BPMC-BPMC&v=1772440688845 "A chart showing the difference between the consensus forecast and the actual stock price. BPMC (BPMC)")
Analyst consensus forecast for stock prices by market segment - Oncology targeted therapy
Blueprint Medicines (BPMC) is a leader in precision oncology. The company masterfully develops targeted drugs for the treatment of cancers caused by rare genetic mutations. This chart shows general expectations for the targeted oncology sector, reflecting experts' belief in the success of precision medicine.
Analysts' consensus forecast for the overall market share price
Blueprint Medicines (BPMC) are the "snipers" in cancer treatment. They develop targeted drugs that attack not just a specific organ (like the lung), but a specific genetic mutation in the tumor. This chart shows the overall risk appetite. It reflects the market's willingness to fund breakthrough but high-risk R&D platforms.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index BPMC
Blueprint is a sniper in oncology. They are a leader in precision medicine: their R&D platform designs small molecules (tablets) that precisely target specific genetic mutations (drivers) that cause cancer (GIST, Masto). This chart is a summary indicator of their R&D machine. It reflects their (growing) sales of approved drugs and their (extensive) pipeline.
AKIMA Market Segment Index - Oncology targeted therapy
Blueprint Medicines is a master of precision oncology. They create targeted drugs that attack specific genetic drivers of cancer, often in patients for whom nothing else works. This chart compares their composite index to the sector, showing how their sniper approach to cancer outpaces others.
The AKIM Index for the overall market
Blueprint Medicines is a precision therapy company developing drugs for cancer and blood disorders (Ayvakit). This chart, reflecting the market average, provides a macro backdrop. It helps assess how BPMC, a successful commercial biotech story, stacks up against the backdrop of overall economic trends.
